Greenstone Biosciences, Inc.

Drug discovery is limited by the lack of relevant preclinical models that adequately capture the complexity and diversity of patients affected. Greenstone Biosciences is building and growing a human iPSC biobank, currently at 2,000+ hiPSC lines, to model diseases with different genetic diversity for drug discovery and to establish “clinical trial in a dish.” We differentiate hiPSCs into multiple cell types, from cardiomyocytes to hepatocytes, to elucidate disease mechanisms and drug response. Furthermore, we synergize hiPSC data with artificial intelligence (AI) methods to improve and de-risk drug discovery in pursuit of safer and more effective drugs for patients. Our services and resources are commercially available to help investigators in academia and industry accelerate their research and drug development pipelines.